Cipla Ltd. share price target

The company looks to expand its lung leadership globally. Key product launches in US market will maximize value opportunities. Company performance is expected to improve with continued efforts on cost optimization and product improvisation. Hence, we reiterate our BUY rating on the stock with a TP of Rs. 1,050 based on 25x FY23E EPS. Sustained growth momentum in core therapies aids topline...

Cipla Q2FY22, PAT rises 7% YoY to Rs 711 crore, beats estimates The drug maker's sales increased 9.56% to Rs 5519.80 crore in Q2 FY22 as compared to Rs 5038.29 reported in Q2 FY21. Its profit before tax increased 7.5% to Rs 995.81 crore in Q2 FY22 as compared to Rs 925.65 reported in Q2 FY21. EBITDA rose 4% year on year to Rs 1,226 crore in Q2 FY22. EBITDA margin for Q2 FY22 stood at 22.2% as compared to 23.4% posted in Q2 FY21. R&D; investments stood at Rs 274 crore in Q2 FY22 with priority projects spends on track....

Q2 revenue/EBITDA grew 10%/4% YoY to Rs 55bn/Rs 12bn, beating our estimates by 6%/4%

Indian branded formulations business accounts for ~40% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal Cipla derives 21% of its export revenues from the US followed by 12% from...

CIPLA delivered an in line result in 2QFY22, led by strong YoY growth in Domestic Formulations (DF) and South Africa. The overall performance was offset by muted showing in the US and API segment....

Q1 revenue/EBITDA grew 27%/28% YoY, beating consensus estimates by 7%/19%

Adding peptide injectables to Respiratory pipeline for US market Motilal Oswal values your support in the Asiamoney Brokers Poll 2021...

Indian branded formulations business accounts for ~40% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal Cipla derives 21% of its export revenues from the US followed by 12% from...

Cipla Q1FY22, Net profit jumps to Rs 715 crore, beats estimates Pharma For the quarter ending June 2021, consolidated net sales (including other operating income) of Cipla has increased 26.65% to Rs 5504.35 crore compared to quarter ending june 2020. Sales of Phamaceuticals segment has gone up 26.21% to Rs 5,384.22 crore (accounting for 97.21% of total sales). Sales of New Ventures segment has gone up 32.39% to Rs 154.70...

South Africa) and better prospects in emerging markets. CIPLA surpassed its guidance of cost saving estimates by Rs4-5bn in FY21 and we believe similar trend to continue in FY22E/23E. Its performance in Q1 was above our estimates given 1) favorable product mix with tailwind in COVID portfolio growth, 2) booster effect on anti-infective portfolio, benefitting peers as well, 3) qualitative improvement in US sales at US$140m and 4) profitable products (in Pvt mkt) aided growth in SA (in CC), despite low tender business. We believe benefits from COVID products to decrease from Q2FY22E, given...